Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: P. Gabriel Steg Clear advanced filters
  • In an analysis of five large randomized clinical trials testing established therapies for cardiovascular disease, individuals with clonal hematopoiesis had an increased risk for first but not recurrent myocardial infarction as compared to individuals without clonal hematopoiesis, and did not show increased benefit from any of the therapies tested.

    • Nicholas A. Marston
    • James P. Pirruccello
    • Christian T. Ruff
    Research
    Nature Medicine
    Volume: 30, P: 2641-2647
  • The time course of events after acute coronary syndromes (ACS) might influence the timing and duration of therapeutic interventions. In this paper the authors study the timing of death, reinfarction, stroke, and major bleeding within 6 months of ACS in 46,829 patients enrolled in the Global Registry of Acute Coronary Events (GRACE). Their data shows that the timing of events after ACS was affected by ST category and influenced by GRACE risk score within each electrocardiographic category of ACS. They recommend that risk stratification should, therefore, include multiple risk factors rather than ST shift alone.

    • Keith AA Fox
    • Frederick A Anderson Jr
    • Joel M Gore
    Research
    Nature Clinical Practice Cardiovascular Medicine
    Volume: 5, P: 580-589
  • Inhibition of factor XI has emerged as a promising strategy to mitigate bleeding while potentially preserving antithrombotic efficacy. In this Review, the authors comprehensively discuss the rationale, pharmacology, evidence and future directions for factor XI inhibitors across various clinical settings.

    • Davide Capodanno
    • John H. Alexander
    • Dominick J. Angiolillo
    Reviews
    Nature Reviews Cardiology
    Volume: 22, P: 896-912
  • Many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. In this Review, Angiolillo and colleagues discuss the pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with cardiovascular disease.

    • Davide Capodanno
    • Deepak L. Bhatt
    • Dominick J. Angiolillo
    Reviews
    Nature Reviews Cardiology
    Volume: 17, P: 242-257
  • ST-segment elevation myocardial infarction (STEMI) is an acute coronary syndrome in which transmural ischaemia (mostly caused by the formation of a thrombus on a ruptured atherosclerotic plaque) leads to cardiomyocyte death. STEMI is associated with considerable morbidity and mortality worldwide.

    • Birgit Vogel
    • Bimmer E. Claessen
    • Roxana Mehran
    Reviews
    Nature Reviews Disease Primers
    Volume: 5, P: 1-20
  • Myocardial infarction is a major cause of morbidity and mortality worldwide. In this consensus document, experts from the ESC, ACCF, AHA, and WHF update the universal definition and classification of myocardial infarction to integrate the latest evidence on the detection of myocardial injury and necrosis using biomarker assays and imaging techniques.

    • Kristian Thygesen
    • Joseph S. Alpert
    • Harvey D. White
    Reviews
    Nature Reviews Cardiology
    Volume: 9, P: 620-633